Logo.png
GRI Bio Participates in Virtual Investor KOL Connect Segment
September 18, 2024 09:00 ET | GRI Bio, Inc.
Albert Agro, PhD, CMO of GRI Bio recently participated in a Virtual Investor KOL Connect segment with prominent key opinion leader in Idiopathic Pulmonary Fibrosis (IPF) – Dr. Helen Parfrey,...
Logo.png
GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 05, 2024 08:45 ET | GRI Bio, Inc.
LA JOLLA, CA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell...
LOgo.png
Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024 18:42 ET | Serina Therapeutics, Inc.
HUNTSVILLE, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery...
Logo.png
GRI Bio to Present at the 2024 European Respiratory Congress
September 04, 2024 08:45 ET | GRI Bio, Inc.
LA JOLLA, CA, Sept. 04, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell...
Logo.png
Harvard Apparatus Regenerative Technology Appoints Mao Zhang to Board of Directors
August 27, 2024 11:15 ET | Harvard Apparatus Regenerative Technology, Inc.
Holliston, MA, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage...
Logo.png
GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 14, 2024 08:05 ET | GRI Bio, Inc.
Company focused on execution of lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) GRI-0621 interim data readout of Phase 2a biomarker study on track for Q4 2024 and...
Logo.png
IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow
July 29, 2024 16:05 ET | Imunon, Inc.
Results to be announced at 8:00 a.m. Eastern time, conference call to begin at 8:30 a.m. Eastern time LAWRENCEVILLE, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a...
LOgo.png
Serina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and Formulation
July 18, 2024 17:00 ET | Serina Therapeutics, Inc.
HUNTSVILLE, AL, July 18, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug...
Logo.png
GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series
July 15, 2024 09:05 ET | GRI Bio, Inc.
Live video webcast on Wednesday, July 17th at 12:00 PM ET LA JOLLA, CA, July 15, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a...
Logo.png
GRI Bio Regains Compliance with Nasdaq
July 08, 2024 09:05 ET | GRI Bio, Inc.
LA JOLLA, CA, July 08, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell...